Health Check: The Future of Healthcare M&A

Facing persistently high interest rates and a shifting regulatory landscape, healthcare and life sciences dealmakers are rethinking their approaches to inorganic growth.

In this exclusive webinar, industry leaders from corporate development and advisory unpacked the top economic and strategic pressures. Our expert panel explored how corporate and private equity dealmakers are:

• Factoring supply chain and tariff disruptions into due diligence
• Identifying subsectors drawing renewed investor interest
• Navigating evolving antitrust enforcement
• Mitigating valuation gaps amid ongoing market uncertainty

Panelists:

• Josh Mastracci, Managing Director, TM Capital
• Dr. Roby Kanichay, Head of Technologies and Externalizations, Global Business Development, Merck Healthcare KGaA
• Daniel Parisotto, PhD, Managing Director, Healthcare Investment Banking, Oppenheimer & Co. Inc.
• Elias El Murr, Director of Investment and Business Development, Opella (Sanofi CHC)

Moderator:

• John Hannan, Director, SS&C Intralinks

Running time:

• 60 Minutes